180 related articles for article (PubMed ID: 34232320)
1. A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
Alhalabi OT; Fletcher MNC; Hielscher T; Kessler T; Lokumcu T; Baumgartner U; Wittmann E; Schlue S; Göttmann M; Rahman S; Hai L; Hansen-Palmus L; Puccio L; Nakano I; Herold-Mende C; Day BW; Wick W; Sahm F; Phillips E; Goidts V
Neuro Oncol; 2022 Jan; 24(1):39-51. PubMed ID: 34232320
[TBL] [Abstract][Full Text] [Related]
2. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
3. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.
de Groot J; Milano V
J Neurooncol; 2009 Nov; 95(2):151-163. PubMed ID: 19436954
[TBL] [Abstract][Full Text] [Related]
4. Conjugation of Dasatinib with MHI-148 Has a Significant Advantageous Effect in Viability Assays for Glioblastoma Cells.
Usama SM; Jiang Z; Pflug K; Sitcheran R; Burgess K
ChemMedChem; 2019 Sep; 14(17):1575-1579. PubMed ID: 31322832
[TBL] [Abstract][Full Text] [Related]
5. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
[TBL] [Abstract][Full Text] [Related]
6. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.
Sun J; Wang X; Tang B; Liu H; Zhang M; Wang Y; Ping F; Ding J; Shen A; Geng M
Theranostics; 2018; 8(12):3256-3267. PubMed ID: 29930727
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.
Finn RS; Aleshin A; Dering J; Yang P; Ginther C; Desai A; Zhao D; von Euw E; Busuttil RW; Slamon DJ
Hepatology; 2013 May; 57(5):1838-46. PubMed ID: 23299860
[TBL] [Abstract][Full Text] [Related]
8. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
9. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
Du J; Bernasconi P; Clauser KR; Mani DR; Finn SP; Beroukhim R; Burns M; Julian B; Peng XP; Hieronymus H; Maglathlin RL; Lewis TA; Liau LM; Nghiemphu P; Mellinghoff IK; Louis DN; Loda M; Carr SA; Kung AL; Golub TR
Nat Biotechnol; 2009 Jan; 27(1):77-83. PubMed ID: 19098899
[TBL] [Abstract][Full Text] [Related]
10. CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.
Avril T; Etcheverry A; Pineau R; Obacz J; Jegou G; Jouan F; Le Reste PJ; Hatami M; Colen RR; Carlson BL; Decker PA; Sarkaria JN; Vauléon E; Chiforeanu DC; Clavreul A; Mosser J; Chevet E; Quillien V
Clin Cancer Res; 2017 Dec; 23(23):7360-7374. PubMed ID: 28939749
[No Abstract] [Full Text] [Related]
11. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
12. Crizotinib targets in glioblastoma stem cells.
Junca A; Villalva C; Tachon G; Rivet P; Cortes U; Guilloteau K; Balbous A; Godet J; Wager M; Karayan-Tapon L
Cancer Med; 2017 Nov; 6(11):2625-2634. PubMed ID: 28960893
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Saha SK; Gordan JD; Kleinstiver BP; Vu P; Najem MS; Yeo JC; Shi L; Kato Y; Levin RS; Webber JT; Damon LJ; Egan RK; Greninger P; McDermott U; Garnett MJ; Jenkins RL; Rieger-Christ KM; Sullivan TB; Hezel AF; Liss AS; Mizukami Y; Goyal L; Ferrone CR; Zhu AX; Joung JK; Shokat KM; Benes CH; Bardeesy N
Cancer Discov; 2016 Jul; 6(7):727-39. PubMed ID: 27231123
[TBL] [Abstract][Full Text] [Related]
15. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
16. SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
Tokuhisa Y; Lidsky ME; Toshimitsu H; Turley RS; Beasley GM; Ueno T; Sharma K; Augustine CK; Tyler DS
Ann Surg Oncol; 2014 Mar; 21(3):1024-30. PubMed ID: 24281418
[TBL] [Abstract][Full Text] [Related]
17. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
19. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
20. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.
Schrage YM; Briaire-de Bruijn IH; de Miranda NF; van Oosterwijk J; Taminiau AH; van Wezel T; Hogendoorn PC; Bovée JV
Cancer Res; 2009 Aug; 69(15):6216-22. PubMed ID: 19602594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
